A corporate announcement detailing expansion of an antiviral research portfolio and intentions to advance a new targeted therapeutic program.
Key Takeaways
- EBV is associated with a range of serious diseases
- "EBV is an increasingly important therapeutic area with substantial medical need
- Innovative Molecules GmbH is a clinical-stage biotechnology company based in Munich